Pharmaceutical-Grade NAD+ Vials Ongoing Provider Care & Support *Prescription products require an online consultation with a healthcare professional who will determine if a prescription is appropriate
The mean duration of type 2 diabetes was 4.2 years, and the mean BMI was 33 kg/m2
approved for the treatment of persons living with obesity with anything beyond a claim of cardiovascular safety." The decision, McGuire said, reinforces what most medical experts have known for decades "that reducing body weight for persons living with obesity would reduce risk for a broad spectrum of obesity-related complications, cardiovascular and otherwise." McGuire, who is an expert in heart disease and prevention, especially among people with diabetes , predicts that approximately one in five U.S
In 2023, a secondary analysis of the trial data was conducted to retrospectively evaluate the risk of atrial fibrillation among the participants (Virtanen 2023)
The study also revealed a statistically significant drop in IOP after starting GLP-1 receptor agonist treatment, especially in those with a history of glaucoma or pre-existing excessive IOP. The researchers also found that GLP-1 agonist use in the management of type 2 diabetes may have possible cardiovascular advantages
